Learn about how Pomalidomide, a cancer drug, shows promise in treating hereditary hemorrhagic telangiectasia (HHT), a rare ...

Hereditary hemorrhagic telangiectasia (HHT) is characterized by extensive telangiectasias and arteriovenous malformations. The primary clinical manifestation is epistaxis that results in iron ...

Purpose Patients with non-proliferative macular telangiectasia type 2 (MacTel) have ganglion cell layer (GCL) and nerve fibre ...

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient ...

A trial found the drug pomalidomide effectively treats hereditary hemorrhagic telangiectasia (HHT), reducing nosebleeds and ...

A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic ...

An NIH-supported clinical trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to ...

Severe nosebleeds caused by hereditary hemorrhagic telangiectasia dwinded in people who took a drug used to treat cancer.

The New England Journal of Medicine published the trial results, which show that patients with HHT who were administered the ...

A clinical trial was stopped early after researchers found that a bone marrow cancer drug, is safe and effective for treating ...

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...